PlatformQ Health is pleased to announce that noted industry leader Seth Gordon has joined the organization in a senior business development and management role, supporting pharmaceutical clients seeking digital solutions to engage and educate healthcare providers and patients online.  Read More

Global cases of Alzheimer’s disease (AD) are expected to triple by 2050, according to a recent study presented at the Alzheimer’s Association International Conference. African American and Hispanic American communities Read More

A pre-recorded, moderated panel discussion featuring stakeholders in CME, patient education, industry, and medical education. Read More

Education about rare diseases is crucial to reducing time to diagnosis and providing optimal care for patients. Recently, PlatformQ Health worked with our strategic partner the National Organization for Rare Read More

The digital education firm PlatformQ Health had two posters accepted at the 2023 American Academy of Neurology Annual Meeting, held in Boston from April 22-27, 2023. The company regularly shares outcomes from its health care provider (HCP) and patient-focused educational programs. During the annual meeting, PlatformQ Health’s posters focused on the results of recent HCP educational programs focused on Rett syndrome and Alzheimer's disease. Read More

PlatformQ Health had 20 posters accepted at major medical and healthcare conferences during 2022. We’re pleased to share the posters, highlighting key outcomes from our educational initiatives across an array Read More

Patients with chronic spontaneous urticaria (CSU) often suffer with unresolved symptoms, despite numerous visits to different healthcare providers. In a recent poster presented at the 2023 American Academy of Allergy, Asthma, and Immunology, PlatformQ Health evaluated the impact of digital continuing medical education (CME) on optimizing diagnosis as well as antihistamine dosing.  Read More

Gastric or gastroesophageal junction (GEJ) adenocarcinomas are notoriously difficult to treat, but recently approved immune checkpoint inhibitors and HER2-directed antibody drug conjugates are improving outcomes for patients with these conditions. While these advances are a positive change, they do pose challenges for healthcare providers who need to learn about new regimens and practices. Read More

As many continuing medication education (CME) program funders will tell you, finding ways to reach medical specialists is often a conundrum. Not only is their time in high demand but they have a plethora of choices when it comes to continuing education. Read More

A Look Back on 2022 - Connecting patients, providers, and caregivers through education As we reflect on the past year, we are particularly grateful for the connections we made with Read More

Vast racial disparities exist in triple-negative breast cancer (TNBC), yet many patients and providers are aware of these issues. Women of the African Diaspora (WAD) are often diagnosed at a more advanced stage and experience higher rates of TNBC-related mortality. Though the TNBC treatment landscape has changed with the influx of new clinical data and newly approved treatments, there is much education needed to ensure patients and the medical community are aware of these advances.  Read More

Targeted treatment regimens have significantly improved overall survival for patients with chronic lymphocytic leukemia (CLL). The emergence of new options such as BTK inhibitors has shifted the treatment landscape significantly, bringing a pressing need for education for providers, patients, and caregivers. Read More